Mirxes Holding (HKG:2629) raised HK$880.5 million in net proceeds from its initial public offering in Hong Kong.
The Singapore-headquartered micro ribonucleic acid technology company issued 46.6 million shares at HK$23.30 each, according to a Thursday filing with the Hong Kong Exchange.
The deal's Hong Kong public offering portion was 25.5 times subscribed, prompting the company to issue 5.87 million shares, up from the 4.66 million shares initially allotted.
The international offering portion was 0.98 times subscribed, and the firm issued 40.7 million shares, lower than the initial allocation of 41.9 million.
The cornerstone investors subscribed to a total of 19.2 million IPO shares.
Mirxes starts trading on the Hong Kong bourse today, May 23.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。